Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Novartis AG — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.77 (market cap $1.45B), while Novartis AG trades at $143.11 (market cap $268.57B). The key difference: Novartis AG is far larger — about 185.2× YieldMax NVDA Option Income Strategy ETF's market cap, and Novartis AG pays a 3.31% dividend while YieldMax NVDA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 43 Days and Novartis AG for 82 Days on average.
| NVDY | NVS | |
|---|---|---|
Market Cap | $1.45B | $268.57B |
Volume | 1,943,739 | 1,532,573 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $168.62 |
52-Week Low | $11.58 | $121.80 |
Typical Hold Time | 43 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $13.01, down slightly by 0.31% on the day. The technical outlook is bullish based on moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The fund generates weekly dividend distributions, with recent payouts ranging from $0.08 to $0.12, but faces criticism for potential net asset value erosion and capped upside participation relative to its underlying asset, NVIDIA stock.
The outlook for NVDY is mixed; it offers high distribution yields but structural limitations may hinder long-term capital appreciation. Investment opportunities include income generation in a low-volatility environment, while risks involve NAV erosion and reduced upside capture if NVIDIA's volatility declines. Analyst sentiment has shifted to hold ratings, reflecting concerns over sustainability.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
